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Purpose: To investigate patients who had transrectal ultrasonography (TRUS)-guided 
prostate biopsy to define the role of the serum testosterone level in predicting prostate 
cancer risk and its association with a high Gleason score. 
Materials and Methods: A total of 568 patients who underwent prostate biopsy were 
entered in this study. We divided the patients into two groups according to serum testos-
terone level (median level, 3.85 ng/ml): the high-testosterone group (n=285) and the 
low-testosterone group (n=283). Multivariate regression analysis was used to define 
the effect of age, prostate volume, serum prostate-specific antigen (PSA) level and PSA 
density, and serum testosterone level on the risk of prostate cancer and a high Gleason 
score. 
Results: Baseline characteristics did not differ significantly between the two groups. 
Compared with the high-testosterone group, the low-testosterone group had a sig-
nificantly higher prostate cancer incidence (38.9% vs. 29.5%, p=0.018). Factors asso-
ciated with an increased risk of prostate cancer were increased age (odds ratio 
[OR]=1.08, 95% confidence interval [CI]=1.25-3.16, p=0.001), a high serum PSA level 
(OR=3.35, 95% CI=2.63-4.25, p=0.001), a low prostate volume (OR=0.183, 95% CI= 
0.11-0.30, p=0.001), and a low serum testosterone level (OR=1.99, 95% CI=1.25-3.16, 
p=0.001). Among these, only the serum PSA level was a strong predictor of high-grade 
prostate cancer (Gleason score ≥7) (OR=2.19, 95% CI=1.57-2.95, p=0.001). 
Conclusions: Patients with lower levels of serum testosterone had a higher risk of pros-
tate cancer than did patients with high serum testosterone. Even though a lower serum 
testosterone level was a predictor of prostate cancer risk, it was not associated with 
an increased risk of high-grade prostate cancer. 
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INTRODUCTION
The morbidity and mortality of prostate cancer is rapidly 
increasing in Korea. Despite some efforts to identify can-
cers with an unfavorable prognosis preoperatively, until 
now, no ideal marker has been recognized. The Gleason 
score of the specimen, pathological stage (TNM 1997), and 
prostate-specific antigen (PSA) are prognostic factors for 
prostate cancer aggressiveness. Although PSA is the lead-
ing marker for prostate cancer, it has a low sensitivity and 
does not have a clear cutoff value that can be used to recom-
mend biopsy. The critical challenge in PSA testing is to dis-
criminate the non-prostate cancer-induced elevation from 
the prostate cancer-related increase in serum PSA. Conse-
quently, an additional screening test is needed that can fur-
ther validate the PSA-weighted risk for prostate cancer in 
the “gray” (4.0-10 ng/ml) diagnostic area. Several parame-
ters have been suggested as surrogate markers, e.g., PSA 
density, PSA velocity, and the free/total PSA ratio, and at-
tempts are being made to develop new markers, such as Korean J Urol 2010;51:819-823
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TABLE 1. Patient characteristics
Total 
patients
High testosterone
(Testosterone≥3.85 ng/ml)
Low testosterone
(Testosterone＜3.85 ng/ml)
p-value
a
No. of patients 568 285 283
Age (yr)  68.8±9.5 68.83±8.8 68.81±10.2 0.978
PSA (ng/ml)  37.79±105.2 41.28±124.7 34.27±81.0 0.321
b
Prostate volume (ml)  45.1±30.5 43.3±28.7   46.9±32.1 0.101
b
Testosterone (ng/ml)  4.0±1.6 5.2±1.4   2.86±0.68 ＜0.001
PSAD 0.98±3.1 1.12±3.7 0.85±2.2 0.298
PSA: prostate-specific antigen, PSAD: prostate-specific antigen density, 
a: Student's t-test, 
b: logarithmically adjusted
prostate-specific membrane antigen and glutathione S- 
transferases [1-3]. Circulating androgens, particularly 
testosterone, are known to play fundamental roles in pros-
tate growth. The underlying mechanism of action remains 
to be identified because androgens mediate complex inter-
actions among many prostate growth factors, hormones, 
and cell lines. As early as 1941, Huggins and Hodges noted 
a close relationship between testosterone and prostate can-
cer [4]. They reported that a noticeable improvement oc-
curred in the clinical status of patients with locally ad-
vanced or metastatic prostate cancer who underwent sur-
gical castration.
　In contrast, some investigators have reported that pros-
tate cancer is often associated with low testosterone levels 
[5,6]. We know that testosterone concentrations drop with 
age and that the incidence of prostate cancer is highest in 
elderly patients. Despite this, the association of serum tes-
tosterone levels with prostate cancer development is not 
completely understood. In the present study, we inves-
tigated patients who underwent transrectal ultrasono-
graphy (TRUS)-guided prostate biopsy to define the role of 
the serum testosterone level in predicting prostate cancer 
risk and its association with a high Gleason score.
MATERIALS AND METHODS
1. Patients
Between January 2005 and May 2009, 568 patients who 
were selected as candidates for TRUS-guided prostate bi-
opsy due to a serum PSA level ＞4 ng/ml or an abnormal 
result on a digital rectal examination were enrolled in this 
study. The patients were grouped according to their serum 
testosterone level (median value, 3.85 ng/ml). The patients 
whose serum testosterone level was 3.85 ng/ml or higher 
were classified as the high-testosterone group, and those 
with a level lower than 3.85 ng/ml were classified as the 
low-testosterone group, respectively. No patients had ever 
received testosterone replacement therapy.
2. Serum testosterone measurement and histopathological 
analysis
Blood samples for testosterone measurement were ob-
tained in the morning before any intervention, when the 
testosterone concentration is relatively stable and is at its 
highest level. The testosterone level was measured by ra-
dioimmunoassay with the use of the DPC total testosterone 
kit (Nippon DPC Corp, Tokyo, Japan). Whereas other stud-
ies have chosen the hypogonadal range as a cutoff value 
[7,8], we applied the median value of serum testosterone 
as the cutoff value.
3. Statistical analysis
The age, PSA, PSA density, and prostate volume of patients 
in the low- and high-testosterone groups were compared by 
using Student's t-test. Rates of prostate cancer in the two 
groups were compared by using Pearson’s chi-square test. 
Multivariate logistic regression analysis was performed to 
determine the correlation between prostate cancer or a 
high Gleason score (Gleason score≥7) and age, total PSA, 
prostate volume, low testosterone, and PSA density. p-val-
ues less than 0.05 were considered statistically significant. 
A statistical software package SPSS ver. 17.0 (SPSS Inc., 
Chicago, IL, USA) was used for all statistical analyses.
RESULTS
1. Patient characteristics
Table 1 shows the characteristics of the 568 patients and 
their mean testosterone levels. The number of patients in 
the high- and low-testosterone groups was 285 and 283, 
respectively. The mean age of all patients was 68.8±9.5 
years, their mean PSA was 37.79±105.2, and their mean 
prostate volume was 45.1 g. The mean serum testosterone 
level of the high- and low-testosterone groups was 5.2±1.4 
and 2.86±0.68 ng/ml, respectively. The mean PSA density 
of the total patients was 0.98±3.1.
　Table 1 also shows a comparison between the high- and 
low-testosterone groups. Baseline characteristics such as 
age, serum total PSA, prostate volume, and PSA density 
did not differ significantly between the 2 groups. Only the 
serum total testosterone level was significantly different 
(p＜0.001). 
　The number of prostate cancer patients in each group 
was 84 and 110, respectively. Patients with low testoster-
one had an increased risk of prostate cancer compared with 
patients with higher testosterone. The ratio of patients 
with a prostate cancer diagnosis was higher among those 
with serum testosterone ≤3.85 ng/ml (38.9 vs. 29.5%; Korean J Urol 2010;51:819-823
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TABLE 2. Relation between prostate cancer and serum testo-
sterone
High 
testosterone
Low 
testosterone
p-value
a
BPH 
Prostate cancer 
201 (70.5%)
  84 (29.5%)
173 (61.1%)
110 (38.9%)
0.018
BPH: benign prostatic hyperplasia, 
a: Pearson chi-square test
TABLE 3. Multivariate logistic regression analysis for estimating prostate cancer risk
Adjusted odds ratio 95% confidence interval p-value
Age 1.08 1.05-1.11 ＜0.001
Serum total PSA (ng/ml)  3.35 2.63-4.25 ＜0.001
a
Prostate volume (ml) 0.183 0.11-0.30 ＜0.001
a
Low testosterone (ng/ml)  1.99 1.25-3.16 ＜0.003
PSAD 0.978 0.77-1.23 0.855
PSA: prostate-specific antigen, PSAD: prostate-specific antigen density, 
a: logarithmically adjusted
TABLE 4. Multivariate logistic regression analysis for estimating a high Gleason score
Adjusted odds ratio 95% confidence interval p-value
Age 0.99 0.94-1.03   0.599
Serum total PSA (ng/ml)  2.19 1.59-3.00 ＜0.001
a
Prostate volume (ml) 0.81 0.39-1.66    0.575
a
Low testosterone (ng/ml) 0.68 0.34-1.34   0.269
PSAD 0.99 0.81-1.22   0.992
PSA: prostate-specific antigen, PSAD: prostate-specific antigen density, 
a: logarithmically adjusted
p=0.018), as shown in Table 2.
2. Correlation between prostate cancer and each variable
Factors associated with an increased risk of prostate can-
cer were increased age (odds ratio [OR]=1.08; 95% con-
fidence interval [CI]=1.05-1.11, p=0.001), a high serum 
PSA level (OR=3.35, 95% CI=2.63-4.25, p=0.001), low pros-
tate volume (OR=0.183, 95% CI=0.11-0.30, p=0.001), and 
a low serum testosterone level (OR=1.99, 95% CI=1.25- 
3.16, p=0.001). PSA density did not have an association 
with increased risk for prostate cancer (p＞0.05) (Table 3).
3. Correlation between Gleason score and each variable
 As shown in Table 4, age, prostate volume, serum testos-
terone level, and PSA density were not associated with the 
Gleason score. Only the serum total PSA level had validity 
for estimating high-grade prostate cancer (OR=2.19, 95% 
CI=1.59 to 3.00, p＜0.001). 
DISCUSSION
In this study, patients with low testosterone had an in-
creased risk of prostate cancer compared with patients 
with high testosterone. Recently, a growing number of 
studies has suggested that low testosterone is associated 
with worrisome features of prostate cancer. For instance, 
lower serum testosterone has been associated with high- 
grade cancer [8-13], more aggressive disease [14], and ad-
vanced pathological stage at the time of radical prostatec-
tomy [15,16].
　Hoffman et al indicated that lower serum-free testoster-
one might be a marker for more aggressive disease [8]. Yano 
et al reported that serum testosterone levels are an in-
dependent significant predictor of a positive prostate biop-
sy [13]. 
　However, the relationship between serum testosterone 
and prostate cancer is not yet clear. Some reports showed 
that there was no relationship between prostate cancer and 
serum testosterone [17,18]. The cause of the association be-
tween high-risk prostate cancer and low serum testoster-
one is still under investigation. One explanation for the as-
sociation between low testosterone and prostate cancer is 
the apparent suppression of testosterone by prostate can-
cer by the hypothalamic-pituitary axis. Miller et al re-
vealed that prostate cancer inhibits testosterone pro-
duction, apparently by local production of inhibin or other 
substances that initiate negative feedback on the hypo-
thalamic-pituitary axis [19]. Indeed, after radical prosta-
tectomy, testosterone concentrations are reported to rise 
sharply [19].
　Also, Risbridger et al evaluated tumor expression of in-
hibin-α in 174 radical prostatectomy specimens and con-
cluded that elevated expression of inhibin-α is related to 
a higher risk of PSA failure [20]. According to Lukkarinen 
et al, these endocrine changes are not seen after simple 
prostatectomy for benign prostatic hyperplasia (BPH) [21]. 
　The correlation between low serum testosterone and 
high-risk prostate cancer could be also secondary to hormo-
nal change in chronic disease [22].
　Schatzl et al reported a statistically significant differ-Korean J Urol 2010;51:819-823
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ence in mean Gleason score between patients with partial 
androgen deficiency (testosterone＜300 ng/dl) and those 
without androgen deficiency (testosterone≥300 ng/dl) 
[12]. Zhang et al found lower testosterone in patients with 
high-grade tumors than in those with moderate grade tu-
mors or in patients with prostate cancer [11]. They classi-
fied patients in the high grade, moderate, or negative group 
according to Gleason score after transrectal prostate 
biopsy. Whereas we classified high-grade cancer from a 
Gleason score of 7, they used a Gleason score of 8 as the cut-
off value. The number in the high-grade group was small 
(n=18). In this study, serum total testosterone did not cor-
relate with Gleason score. There is no clear reason for this 
discrepancy. Genetic factors and environmental factors 
might be responsible for the discordance, but further study 
would be required to resolve this question. As expected, the 
serum total PSA level was a significant factor for estimat-
ing the Gleason score (adjusted OR=2.19; 95% CI=0.34 to 
1.34, p＜0.001). 
　There are some differences between our study and others. 
Most other studies grouped patients according to biopsy re-
sults, whereas we divided the patients according to testos-
terone level. We consider the testosterone level to be a more 
relevant classification for identifying the relationship be-
tween testosterone level and prostate cancer. Also, in our 
study, we used the median value of testosterone as a cutoff 
value, whereas other studies applied the hypogonadal 
range to sort patients into the high- and low-testosterone 
groups. Moreover, there is the possibility of selection bias 
in other studies owing to age-matched grouping.
　Besides testosterone, estrogen modulates prostate growth, 
differentiation, and function in several ways [23]. In addi-
tion, estrogen is considered to be one of the hormonal risk 
factors in the development of prostate cancer [24,25]. The 
principle source of estrogen in men is the aromatization of 
androgens to estrogens, which takes place predominantly 
in fatty tissue. Estradiol promotes prostate epithelial cell 
growth through binding of the estrogen receptor-α and in-
hibits growth by effects mediated through the estrogen re-
ceptor-β [23]. Signoretti and Loda demonstrated that the 
estrogen receptor-β also plays an important role in the ini-
tiation of prostate cancer [26]. Hsing et al concluded that 
estrogens may have anti-tumor action through their effects 
on the hypothalamic-pituitary axis, whereas at physiologic 
levels, estrogen, alone or in conjunction with androgens, 
may promote tumor growth [27].
　Although several studies have revealed the relationship 
between estrogen and prostate cancer, its role is still 
controversial. Further prospective studies are essential to 
demonstrate the true relationship. 
　Our study had some limitations, including its retro-
spective nature and the absence of data for free testo-
sterone. Actually, free testosterone is considered the more 
biologically active form and may be fundamental in pre-
dicting prognosis. Hoffman et al obtained results suggest-
ing that low serum free testosterone is a marker of more 
aggressive disease [8]. Because our results depended on 
transrectal prostate biopsy, we did not include more pre-
cise data such as clinical stage, surgical margin, or can-
cer-specific survival. The true association between low tes-
tosterone and prostate cancer in the long term needs vali-
dation in large prospective studies. 
CONCLUSIONS
Patients with lower levels of serum testosterone had a 
higher risk of prostate cancer than did those with high se-
rum testosterone. Even though a lower serum testosterone 
level was a predictor of prostate cancer risk, it was not asso-
ciated with an increased risk of high-grade prostate cancer. 
Further prospective studies are needed to explain the rela-
tion between a low serum testosterone level and a poor 
prognosis of prostate cancer.
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